Metrion: research consortium aiming to reduce animal studies, facilitate new drug development

By Melissa Fassbender contact

- Last updated on GMT

The project is titled “Developing an ethical, sustainable, human sensory neuron cell culture model for use in therapeutic pain research,” or DRGNET. (Image: iStock/bodym)
The project is titled “Developing an ethical, sustainable, human sensory neuron cell culture model for use in therapeutic pain research,” or DRGNET. (Image: iStock/bodym)

Related tags: Nervous system

Metrion Biosciences (Metrion), an ion-channel and drug discovery CRO, has joined a network of partners to evaluate the use of primary human dorsal root ganglion (hDRG) neurons in pain research.

The CRACK IT "DRGNET" Human Pain Research Consortium's aim is to augment research efficiency by creating a system that supplies high quality and viable human DRG neurons to both industrial and academic researchers.

Consequently, the Consortium hopes to in some measure override current methods, which use isolated cells or tissues from animals, or in vivo animal testing.

According to Metrion​, the systems’ successful implementation will increase understanding of the human system, and facilitate drug target identification and novel pain therapeutic development.

Specifically, the Consortium anticipates that the project will result in a human sensory neuronal model, for mechanistic understanding and compound screening.

By increasing the understanding of human DRG neurons, Metrion said stem cell-derived sensory neurons could potentially be used in high throughput and high content screening of new drug candidates.

Metrion is supporting the project as an industrial sponsor, replacing a role previously held by Pfizer-Neusentis. The company will be responsible for evaluating and characterizing the human nerve cells.

The project is titled “Developing an ethical, sustainable, human sensory neuron cell culture model for use in therapeutic pain research​,” or DRGNET. It is led by the University of Glasgow​ and funded from the NC3Rs as part of their CRACK IT Challenges open innovation initiative.

The surgical staff at NHS-GGC​ will retrieve human DRGs from organ transplant donors with support from NHS Blood & Transplant​ before research staff from the University and its partners extract viable sensory neurons.

Related news

Show more

Related products

show more

The Complexities of Ophthalmic Drug Development

The Complexities of Ophthalmic Drug Development

Altasciences | 04-Oct-2022 | Technical / White Paper

Ophthalmic drug development comes with a unique set of challenges that can be mitigated by working with an end-to-end solution provider with regulatory...

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

Strategic Approach to Immunogenicity Assessment

Strategic Approach to Immunogenicity Assessment

Altasciences | 17-May-2022 | Technical / White Paper

In this issue of The Altascientist we provide a detailed overview on the different goals and challenges that are presented by the validation of immunogenicity...

Related suppliers

Follow us

Products

View more

Webinars